Advanced Cancer
Conditions
Brief summary
This is a Phase 1 study during which patients with advanced solid tumors will receive investigational study drug ARRY-142886. This study has 2 parts. In the first part, patients will receive increasing doses of study drug in order to achieve the highest dose of study drug possible that will not cause unacceptable side effects. Approximately 25 patients from the US will be enrolled in Part 1 (Completed). In the second part of the study, patients will receive the best dose of study drug, determined from the first part of the study, and will be followed to see what side effects the study drug causes and what effectiveness the study drug has, if any, in treating the cancer. Approximately 35 patients from the US will be enrolled in Part 2 (Completed).
Interventions
DRUGARRY-142886, MEK inhibitor; oral
Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
Sponsors
Array Biopharma, now a wholly owned subsidiary of Pfizer
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria (Part 2): * Histopathologically or cytologically confirmed solid tumor that is refractory to standard therapies, or for which no standard therapies exist, or for which the Investigator feels no other active therapy is required for the duration of the study. * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2. * Estimated life expectancy of greater than or equal to 3 months. * Patient must have a tumor that is accessible for biopsy and must consent to paired tumor biopsies and normal skin biopsies being taken pre- and post-dose of study drug. * Additional criteria exist. Key
Exclusion criteria
(Part 2): * Uncontrolled or symptomatic brain metastases. * Use of investigational drug or device within 30 days prior to first dose of study drug. * Major surgery within 30 days prior to study start. * Radiotherapy or chemotherapy within 21 days prior to study start (not including palliative radiotherapy at focal sites). * Pregnancy or lactation. * Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C. * Additional criteria exist.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests, vital signs and electrocardiograms. | Part 1 |
| Establish the maximum tolerated dose (MTD) of study drug. | Part 1 |
| Assess the biological activity of the study drug in tumors in terms of inhibition of extracellular signal-regulated kinase (ERK) phosphorylation. | Part 2 |
Secondary
| Measure | Time frame |
|---|---|
| Characterize the pharmacokinetics (PK) of the study drug in terms of plasma concentrations. | Part 1 and Part 2 |
| Confirm the safety of the study drug at the MTD as determined by adverse events, clinical laboratory tests, vital signs and electrocardiograms. | Part 2 |
| Characterize the pharmacodynamic (PD) activity of the study drug on biomarkers. | Part 1 and Part 2 |
| Assess the efficacy of the study drug in terms of tumor dimension assessment. | Part 1 and Part 2 |
Countries
United States
Outcome results
None listed